Introduction
Follicular lymphoma (FL) is the second most frequent type of malignant lymphoma (NHL), accounting for up to 20% of lymphoma patients. Only diffuse large B-cell lymphoma (DLBCL) is more common. 1 The course of disease is highly variable with a median survival time of 8 to 10 years. 2 Patients can show slow progression over a period of 20 years, while on the other hand tumors can be aggressive resulting in death within less than one year. 3 Identification of these patients is still challenging and has impact on therapeutic modalities. Long-time remission is possible in early Ann Arbor stages I or II, which account for at most 15% of patients. For patients with advanced lymphoma stages III and IV, therapy is usually not initiated until the disease becomes symptomatic. 2 After this period of watchful waiting, there is often good initial response to various kinds of therapies. 4 As patients relapse over time, durations of remission get shorter and finally patients die either of progressive disease or after transformation into DLBCL.
This occurs in about 30% of tumors after accumulation of numerous genetic alterations. 5 However, it appears questionable whether such random events in the genome of tumor cells are responsible for the clinical heterogeneity of the disease. 6 The follicular lymphoma international prognostic index (FLIPI) represents a effective clinical scoring system to estimate prognosis in FL. It includes patients' age (older than 60 years versus 60 years and younger), Ann Arbor stage (III/IV versus I/II), number of lymph node sites affected (more than 4 versus up to 4), hemoglobin level (less versus at least 120 g/L) and serum LDH level (above normal versus normal). 7, 8 However, it does not include intrinsic tumor properties. For a long time, the only Page 4/28 prognostic features within the tumor itself were histological grading according to WHO criteria or determination of the proliferation index. 9, 10 Increasing evidence points to a role of tumor stroma, especially intratumoral reactive cells in determinating the course of disease and in modulating tumor progression by changing microenvironmental properties and by interacting with tumor cells. 6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Intratumoral leucocytes were described already 150 years ago by Rudolf Virchow, who suggested a connection between chronic inflammation and cancerogenesis.
Esophageal adenocarcinoma and pleural mesothelioma are well-known examples of inflammation induced malignancies. T cells, macrophages and dendritic cells are found in various malignant diseases. They have been associated with prognosis, sometimes favourable, sometimes poor. 21 Gene expression studies identified T cells, macrophages and dendritic cells to impact on prognosis in FL. 6, 13, 14 In this study, we intended to emulate these results on tissue sections. We focused on CD123+ pDC, as they are known to have various immunoregulatory functions. 22 Macrophages, T cell subsets and vessel density have been adressed by others. [14] [15] [16] [17] [18] [19] 23 Of note, pDC produce important amounts of type-I-interferon during maturation, especially interferon-alpha (IFN-α) [24] [25] [26] , and IFN-α was used with success in the therapy of FL prior to the advent of CD20 targeting therapy regimen.
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Patients, materials and methods
PATIENT CHARACTERISTICS
Patients were retrieved by searching the pathology information system of the 33 Multivariate survival analysis and hazard ratio estimation was done by Cox regression. The assumption of constant hazard over time was proven by means of log minus log plots. 34 Cases with lack of data were excluded from the Cox models. For all purposes, overall survival (OS) was defined as the period from date of biopsy until death of any cause. Furthermore, we used a non-parametric method (Spearman rank correlation) to determine correlations. For crosstabulation analysis
Fisher's exact test was applied.
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Results

PATIENT CHARACTERISTICS, CLINICAL AND PATHOLOGICAL VARIABLES
139 patients were included in our study and their characteristics are listed in (table III) . Patients were also divided in groups whether or not they were treated with an anthracycline based chemotherapy and whether or not the therapy contained the anti-CD20 agent rituximab. However, no significant difference in survival was found between these groups (table III) . PDC are typically found within T cell rich interfollicular areas of lymphoid tissue. 32 We included this compartment in our analysis by means of staining for CD3+ T cells.
PLASMACYTOID DENDRITIC CELLS AND T CELLS
Evaluation equally showed an association with the clinical course, similar to that of CD123+ pDC. High CD3+ T cell contents are also associated with longer survival.
However, differences are less pronounced. Because a certain correlation of both cell types could be expected due to their presence at the same lymph node compartment, a test for redundancy of these results appeared mandatory: On the one hand, the correlation of pDC and T cell content was shown to be weak. On the other hand, in a multivariate Cox regression model, only the pDC content proved to be an independent prognostic factor (table IV) . Thus, CD123+ pDC do not seem to represent a surrogate measure for loss of the interfollicular T cell compartment during tumor progression. Rather, pDC appear to have prognostic impact beyond. CD123. An association of WHO grade with CD123+ cell numbers can thus not explain the association of CD123+ cell numbers with longer survival.
The results of the multivariate analysis for WHO grade and CD123+ cell numbers (Table 3) show a lack of statistical significance for WHO grade in both univariate and multivariate analysis.
PDC have been reported in FL, where they have also been associated with T cell subsets. 17 PDC have also been described in solid tumors like head and neck squamous cell carcinoma, lung cancer and melanoma. 22, 35 However, to our knowledge, no direct association with patient's survival prognosis was previously found and their role in tumor biology remains unclear. 35 There is evidence that pDC can infiltrate tumor tissue, though their proper antigenpresenting capacity might be disabled under these conditions and induction of tolerance could result instead. 35, 36, 37 Indeed, under tumor conditions, the function of pDC's has been described to be altered even at sites away from the tumor, i.e. within lymphatic tissue and in blood. 38, 39 On the other hand, pDC perform various functions in innate as well as in adaptive immune response. They have been shown to be the most prominent cells to produce interferon, especially IFN-α, a type-I-Interferon.
22,24-
26
Interferons have immunomodulating and antitumor activity. 40, 41 Remarkably, IFN-α was used with success in therapy of FL before the introduction of rituximab. 27 Its role in current treatment is controversial. 40, 42 It is tempting to speculate that pDC provide IFN-α endogenously, which otherwise would be provided by external sources, and Page 14/28 that this endogenous secretion results in longer survival of patients with high pDC numbers.
Upcoming immunomodulatory therapies include this aspect already: The anti-CD20 monoclonal antibody rituximab, introduced in 1997 for therapy of low-grade lymphomas, has been a great success. 43 It is administered as a single agent or in multiagent chemotherapy like R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone). 44 However, most patients with FL relapse at some point and new approaches are needed. One focus of study is to combine rituximab with immunomodulatory agents to tap its full antitumoral potential.
Randomized studies that examine rituximab with IFN-α are indeed ongoing. 
LIMITATIONS
The examination was performed on a tissue microarray. The technique is widely used to study lymphoma by examining the expression profile of neoplastic cells as well as of non tumor cells. [15] [16] [17] 48, 49 Validation studies of this approach have shown excellent results for many biomarkers. 29 However, a correlation study of TMA versus full tissue sections of FL could ensure the representativity of the cores stained for CD123. This is of particular interest as PDC are found mainly in the interfollicular areas and the distribution in the tissue is therefore uneven.
In our study, we did not account for the causes of death. For the majority of patients, precise information was not available. Autopsy was performed only for a small percentage of patients. On the other hand, the use of death of any cause could avoid issues of exact delineation of lymphoma related death vs. non lymphoma related death in patients with multiple co-morbidity. Therefore, we decided not to concentrate on disease-related causes of death und instead used overall-survival for statistical purposes.
Therapy of our study population was adapted to patients' age, stage and symptoms.
One third of the patients were treated using anthracyclines in first-line chemotherapy, whereas two-thirds received anthracyclines at some point during their whole clinical course. Rituxin and radiotherapy were each applied in another third of patients.
Indeed, follicular lymphoma is a heterogeneous disease in need for patient adapted therapy. Reducing patients to an uniformly treated collective would have resulted in the exclusion of a majority of patients and in a relevant loss of statistical power.
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However, our findings are sufficiently striking, easily reproducible and therefore worth to be investigated in an independent validation-set of patients.
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